• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Pharma Equity Group: Præsentation af delårsregnskabet for H1 2026 (Optagelse)

PEGAnalyst Comment14.08.2026, 15.27
Michael FriisHead of Equities

Pharma Equity Group offentliggjorde i dag sit delårsregnskab for første halvår af 2026. I den forbindelse havde vi i dag fornøjelsen af at have CEO Christian H. Tange, der gennemgik resultaterne og highlights for halvåret samt forventningerne til 2026, og svarede på spørgsmål fra publikum.

Se eller gense eventet her:

PEG - H1-2026 event

Disclaimer: HC Andersen Capital modtager betaling fra Pharma Equity Group for en Digital IR/Corporate Visibility abonnementsaftale./Michael Friis 14/08-2026, kl. 15:27.

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Read more on company page